Pharmacological blockade of the EP3 prostaglandin E2 receptor in the setting of type 2 diabetes enhances β-cell proliferation and identity and relieves oxidative damage by Karin J. Bosma, Spencer R. Andrei, Liora S. Katz, Ashley A. Smith, Jennifer C. Dunn, Valerie F. Ricciardi, Marisol A. Ramirez, Sharon Baumel-Alterzon, William A. Pace, Darian T. Carroll, Emily M. Overway, Elysa M. Wolf, Michelle E. Kimple, Quanhu Sheng, Donald K. Scott, Richard M. Breyer, Maureen Gannon

Connect to this object online.